Half the Population. A Field Finally Being Built for Them.
Regulatory strategy for women's health — where the science is catching up on decades of exclusion and pregnancy is still the hardest population to study.
For Decades, Half the Population Was a Regulatory Afterthought.
Women were once routinely excluded from clinical trials, and the drugs they took were dosed and labeled on data drawn from men. That legacy still shapes the field: gaps in sex-specific evidence, conditions that went understudied for a generation, and a pregnant population treated as a therapeutic orphan.
The correction is underway — sex as a biological variable, the Pregnancy and Lactation Labeling Rule, and a real push to include pregnant and lactating people in research. We build women's-health programs to meet the evidence standard the field is finally reaching for, not the one it inherited.
Sex differences in pharmacology are real and regulated — the evidence has to reflect the patients who will take the drug.
The Regulatory Story of Women's Health Is a Story of Getting on the Record.
Four turning points reshaped how women's health is studied and labeled. Knowing where the field has been explains exactly what the FDA now expects — and where the evidence still has to catch up.
Exclusion
Women of childbearing potential were kept out of early trials — a caution that became a decades-long evidence gap.
Inclusion Mandated
The NIH Revitalization Act and FDA guidance required women in trials and analysis of sex differences.
PLLR
The Pregnancy and Lactation Labeling Rule replaced letter categories with narrative, risk-based labeling.
Studying Pregnancy
A concerted push to responsibly include pregnant and lactating people, so they are no longer therapeutic orphans.
From Contraception to Postpartum Neuroscience.
Women's health spans distinct endpoints and divisions — some with decades of precedent, some being written right now.
Contraception
Where the Pearl Index and typical-use efficacy anchor a mature pathway spanning hormonal, non-hormonal, and device methods.
Menopause & HRT
Where the Women's Health Initiative reset benefit–risk, and non-hormonal vasomotor therapies opened a new evidence conversation.
Endometriosis & Fibroids
Long-underserved conditions where pain and bleeding endpoints, patient-reported outcomes, and long-term safety define the program.
Maternal-Fetal Medicine
Where every decision weighs two patients at once, preterm-labor history looms large, and evidence is hardest to generate.
Postpartum & Mental Health
Where postpartum depression became a defined indication with rapid-acting therapies — women's health meeting neuroscience.
Bone & Postmenopausal Health
Osteoporosis and postmenopausal conditions, where bone density is a surrogate and fracture reduction is the outcome.
Pregnant patients get sick and need treatment — yet remain the population we have the least evidence for.
The Hardest Labeling Problem in Medicine Is Also the Most Important.
The Pregnancy and Lactation Labeling Rule swept away the old A/B/C/D/X categories in favor of a narrative that summarizes real risk, clinical considerations, and the data behind them. It demands more than a letter — it demands evidence, often from pregnancy exposure registries and post-marketing data rather than pre-approval trials.
We build the PLLR labeling strategy and the pregnancy and lactation evidence plan — registries, pharmacokinetic studies, and the responsible-inclusion approach the FDA and the PRGLAC agenda now encourage — so the label actually helps the clinician and the patient.
Under-Studied Is Not the Same as Un-Approvable.
The very gaps that held women's health back are now where the clearest unmet need — and the strongest regulatory receptivity — sit. The field rewards sponsors who bring rigorous evidence to questions that were ignored for too long.
narrative labeling means a real evidence plan — registries, PK in pregnancy, lactation studies — not a default category assignment.
Pregnancy exposure registries and real-world data are central to the label — build them into the lifecycle from approval, not after.
Endometriosis, menopause, and postpartum disease are large, under-served markets where regulators welcome well-designed programs.
Six Failure Modes We Are Brought In to Prevent.
Often the program inherited the field's old assumptions instead of meeting its new expectations.
No pregnancy or lactation plan
Reaching approval without a PLLR-ready evidence strategy, then facing a label that can't guide the clinicians who will prescribe it.
Underpowered on a subjective endpoint
Endometriosis and vasomotor programs built on pain or symptom endpoints without the design to separate signal from a large placebo response.
Ignoring the preterm-labor precedent
A maternal-health program that didn't learn from the accelerated-approval and confirmatory history that reshaped the field's benefit–risk bar.
Registries planned after launch
Treating pregnancy exposure registries as a post-approval afterthought rather than a designed, adequately powered evidence source.
Sex-difference analysis skipped
Failing to plan the sex-specific analyses and dosing questions the division now expects across every indication.
Crossing divisions unprepared
A postpartum-CNS or bone program that didn't coordinate the women's-health and neuroscience or endocrine expectations it sits between.
Women's-Health Regulatory Leadership for the Evidence Era.
Our women's-health leads have designed contraception, endometriosis, and postpartum programs, built PLLR labeling and pregnancy registries, and navigated the inclusion expectations reshaping the field.
"Women's health was under-studied for a generation. The programs that lead now are the ones that bring real evidence — including in pregnancy — to the questions that were ignored for too long."
The discipline we bring across contraception, menopause, endometriosis, maternal-fetal, and postpartum disease.
Developing a Women's-Health Therapy? Build to the Standard the Field Is Reaching For.
Bring senior women's-health regulatory leadership in early — while the endpoints, pregnancy strategy, and labeling plan are still yours to shape.
Senior-led. Embedded in your team. No junior hand-offs.